It’s not often you get excited talking about company mergers, but a deal announced today is something worth getting excited about, particularly if you have type 1 diabetes (T1D). Today Vertex announced it was buying ViaCyte for $320 million in cash. Why is that important? Because both companies are working on developing stem cell therapies … Continue reading A big deal for type 1 diabetes
Michael Yang
Type 1 diabetes therapy gets go-ahead for clinical trial
ViaCyte's implantable cell-based therapy for type 1 diabetes THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Taking even the most promising therapy and moving it out of the lab and into people is an incredibly complex process and usually requires a great team. Now, two great teams have paired up to do just that … Continue reading Type 1 diabetes therapy gets go-ahead for clinical trial
The Stem Cellar 